REPL Replimune Group, Inc.

XNAS 11.99 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

REPL $11.99 —
Key stats
$11.99
After hours $11.93 -0.49%
52-Week Range
$1.50 – $16.33
YTD
+34.72%
IV Rank (30D)
10.42
Straddle Price
$3.40
P/C Vol Ratio
0.25
Market Cap
$1.1B
Open
$11.70
Day Range
$11.53 – $12.01
Volume
1,760,537
Prev Close
$11.72
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.84
Cost of Equity (CAPM)9.33% (VRP-adj)
WACC8.94%
Volatility Risk Premium+128.1pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.3B
Return on Equity (TTM)-281.1%
Book / Price15.4%
Debt / Equity0.63
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$13.67 (Market Anchor value)
SMA 20 / Bollinger Mid$12.49
Bollinger Width / SMA20210.9% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: ABBV, AXSM, BTSG, GH, LLY, NVS, ROIV, RVMD
60-Day Conviction
62%
20-Day Fair Value
≈ by Nov 20, 2026
$12.04
α +0.4% rank 61%
conviction
26%
40-Day Fair Value
≈ by Dec 21, 2026
$12.23
α +2.0% rank 64%
conviction
62%
60-Day Fair Value
≈ by Jan 19, 2027
$12.21
α +1.8% rank 63%
conviction
62%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 43.0× · 4 peers
Peer EV/EBITDA n/a 0% median 23.5× · 4 peers
Peer P/B $20.02 28% median 11.1× · 6 peers
Peer P/S n/a 0% median 10.8× · 7 peers
Market Anchor (SMA50) $13.67 0% stability 0% (BB-width)
Options Expected (B-L 30d) $10.36 72% 28 strikes · skew -0.17
As of 2026-10-22 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$1.1B
Employees
465
List Date
2018-07-20
CIK
0001737953
Next Earnings
2026-11-05 (After-Close)
EPS Forecast
($0.70) (4 est.)
Headquarters
Woburn, MA
Homepage
https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan1.49%-32.34%5.69%-10.50%11.31%-21.01%-7.56%
Feb-11.79%-17.19%-23.40%9.16%-7.51%9.68%-6.84%
Mar-13.86%6.26%-20.84%-8.92%-19.55%6.84%-8.35%
Apr15.86%-8.16%-4.78%-17.85%16.43%-66.23%-10.79%
May6.04%-13.61%8.51%-18.67%-6.85%247.60%37.17%
Jun3.09%19.89%25.65%65.44%-2.93%23.00%22.36%
Jul-16.53%4.90%-3.88%6.84%-23.17%0.18%-5.28%
Aug-4.77%1.49%-0.58%-0.49%-28.95%28.46%-0.81%
Sep-10.94%-9.91%-13.24%6.61%-28.98%-15.51%-11.99%
Oct-0.14%7.24%-7.73%-1.18%131.12%-10.86%*19.74%
Nov-7.53%7.40%-21.76%18.32%7.47%--0.78%
Dec-3.25%36.14%-28.01%-10.63%0.10%---1.13%
Total-38.23%-14.83%-64.15%16.49%-15.95%29.53%-14.52%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $12.46
SMA 50: $13.60
SMA 200: $9.11
Current: $11.99
EMA 12: $11.98
EMA 26: $12.48
MACD: -0.4982 | Signal: -0.0759
BEARISH
ADX (14): 20.77
WEAK TREND
+DI: 16.09
−DI: 24.42

Momentum Oscillators

RSI (14): 44.87
NEUTRAL
Stoch %K: 34.00
Stoch %D: 23.18
Williams %R: -54.95

Volume & Volatility

BB Upper: $14.11
BB Lower: $10.80
NEUTRAL
OBV: 325,409,633
Vol SMA 20: 2,003,832
Vol ROC: 0.73%
ATR: $0.76
True Range: $0.48
HV 20: 56.7%
HV 30: 50.9%
HV 60: 162.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-22T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

BULLISH (Confidence Level: 7/10)

Key Drivers:

  • Technical indicators suggest a bullish trend, with MACD and RSI indicating momentum
  • Recent news headlines highlight positive sentiment, particularly the FDA advisory committee meeting outcome

Primary Risks:

  • High volatility, reflected in beta value of 1.34
  • Negative news headlines about class-action lawsuits may impact investor confidence

Investment Thesis:

REPL is a high-growth biotech stock with significant potential for upside, driven by its innovative cancer treatment approach and recent FDA advisory committee meeting outcome. However, investors should be aware of the company's exposure to class-action lawsuits and potential volatility.

Recent News Sentiment Impact:

The positive news headlines about the FDA advisory committee meeting outcome have contributed to the bullish sentiment, while negative headlines about class-action lawsuits may weigh on investor confidence.

Technical Analysis

Trend Direction:

  • Short-term: Bullish (upward momentum)
  • Medium-term: Bullish (MACD and RSI indicate momentum)
  • Long-term: Neutral (no clear direction)

Support/Resistance Levels:

  • SMA 20: $15.07
  • Upper Bollinger Band: $16.39

Momentum Signals:

  • MACD signal line is above the zero line, indicating bullish momentum
  • RSI is neutral at 56.63%, suggesting no overbought or oversold conditions
  • Williams %R is -51.19%, indicating oversold conditions (potential buy signal)

Volume Analysis:

  • Volume SMA 20: 3177584.91
  • On-Balance Volume (OBV): 330717782.72
  • Volume Rate of Change: -69.42% (indicating reduced trading activity)

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines about FDA advisory committee meeting outcome and company's innovative approach to cancer treatment
  • Negative news headlines about class-action lawsuits and potential legal issues

Sentiment Assessment:

  • Aggregate sentiment is NEUTRAL, with a slight BULLISH bias due to recent positive news headlines

Catalyst Identification:

  • Upcoming earnings report (no specific date available)
  • Regulatory approvals or setbacks for RP1 in advanced melanoma treatment

Market Narrative:

The technical indicators and recent news headlines suggest a bullish trend, while the negative news about class-action lawsuits may weigh on investor confidence. The market narrative is NEUTRAL to BULLISH.

Risk & Volatility Assessment

Beta Interpretation:

  • Beta value of 1.34 indicates high volatility relative to the market

Volatility Regime:

  • Current volatility level is HIGH compared to historical averages

Options Market Signals:

  • IV rank: 5.7% (Low - shows if volatility is historically high/low)
  • Put/call volume ratio: 0.40 (Bullish sentiment)

Downside Protection:

  • Support levels at SMA 20 and Bollinger Band middle line
  • Risk management considerations include stop-loss levels and position sizing

Market Context & Positioning

Sector Performance:

  • Relative strength vs sector/market is NEUTRAL to BULLISH

Institutional Activity:

  • Volume patterns suggest institutional interest in the stock

Correlation Analysis:

  • Correlation with SPY is 0.08, indicating low correlation

Relative Valuation:

  • Position within trading range is NEUTRAL to BULLISH

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $15.07
  • Upper Bollinger Band: $16.39

Breakout/Breakdown Levels:

  • None identified based on technical indicators and recent price action

Time-Sensitive Catalysts:

  • Upcoming earnings report (no specific date available)
  • Regulatory approvals or setbacks for RP1 in advanced melanoma treatment

Risk Management:

  • Stop-loss levels at SMA 20 and Bollinger Band middle line
  • Position sizing considerations include reducing exposure to minimize potential losses
Generated
News
All REPL news →
Earnings History
15 of 15 under expected move
Avg Expected Move
12.85%
Avg Actual Move
2.49%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-05-20 After-Close 5.01% 0.86% 0.17x Within
2023-02-09 After-Close 25.87% 2.27% 0.09x Within
2023-05-18 After-Close 8.30% 0.31% 0.04x Within
2023-08-03 After-Close 12.46% 2.78% 0.22x Within
2023-11-07 After-Close 16.44% 6.56% 0.40x Within
2024-02-08 After-Close 10.36% 0.52% 0.05x Within
2024-08-08 After-Close 22.22% 1.38% 0.06x Within
2024-11-12 Pre-Market 8.20% 2.48% 0.30x Within
2025-02-12 After-Close 17.22% 3.63% 0.21x Within
2025-05-22 Pre-Market 28.96% 3.55% 0.12x Within
2025-08-07 After-Close 5.93% 3.47% 0.59x Within
2025-11-06 Pre-Market 7.87% 0.93% 0.12x Within
2026-02-03 After-Close 9.82% 5.15% 0.52x Within
2026-06-29 After-Close 9.82% 1.16% 0.12x Within
2026-08-14 After-Close 4.34% 2.27% 0.52x Within

Earnings calendar: this week’s reports with expected vs actual moves →

REPL Options Activity & IV Rank

REPL IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 104.5%
7-DTE IV: 82.5%
Expected Move: $3.40
7-DTE Move: $1.17
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 1,232
Put Volume: 304
P/C Volume: 0.247
BULLISH
Call OI: 20,975
Put OI: 6,504
P/C OI: 0.31
Total OI: 27,479

ATM Options Pricing

ATM Call: $1.20
ATM Put: $2.20
Call %: 10.0%
Put %: 18.3%

Chain Summary

Chain Volume: 11,280
Chain OI: 94,927
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 67th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
67%
vs own history
GEX tilt
+0.31
OI-weighted, today
Vanna tilt
+0.73
δ-sensitivity to IV
Charm tilt
-0.62
δ-decay vs time
Vanna tilt +0.73: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.62: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 35 ATM contracts, 13k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM 90.4% / Wing —
30 DTE / 10d 25%
+0.5 pts EXTREME
ATM 98.4% / Wing 99.0%

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)4.1LowOct 22
IV Rank (30 DTE)10.4LowOct 22
Straddle Price (30 DTE)$3.40Oct 22
Beta Analysis

Risk Metrics

Beta: 1.0424
Alpha: 180.91%
Correlation: 0.0707
R-Squared: 0.5%
Stock Volatility: 186.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 250
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own REPL
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$9.1M
0.01%
#1636 of 3716+173.2%13F
Citadel Hedge fund
Ken Griffin
$8.7M
0.00%
#1693 of 6285+96.7%13F
Point72 Hedge fund
Steve Cohen
$8.0M
0.01%
#828 of 1945new13F
Renaissance Technologies Hedge fund
Jim Simons
$441K
0.00%
#2646 of 3138-89.6%13F
Rockefeller Capital Management Family office
Rockefeller family
$25K
0.00%
#3660 of 4729new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

REPL Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 92,105,815 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

203 filers99,352,714 shares$1.10B value107.87% of float
# Filer Shares Value % of Total % of Float Period
1 BAKER BROS. ADVISORS LP 11,045,336 $122.27M 11.17% 11.99% 2026-06-30
2 BlackRock, Inc. Custodian 8,958,535 $99.17M 9.06% 9.73% 2026-06-30
3 RTW INVESTMENTS, LP 7,411,581 $82.05M 7.49% 8.05% 2026-06-30
4 Ridgeback Capital Investments L.P. 7,310,656 $80.93M 7.39% 7.94% 2026-06-30
5 Goldman Sachs Group Inc Custodian 4,541,018 $50.27M 4.59% 4.93% 2026-06-30
6 State Street Corp 4,440,144 $49.15M 4.49% 4.82% 2026-06-30
7 MONTANOVA CAPITAL, LLC 4,389,836 $48.60M 4.44% 4.77% 2026-06-30
8 Boxer Capital Management, LLC 3,983,000 $44.09M 4.03% 4.32% 2026-06-30
9 Vanguard Group Inc Custodian 3,776,198 $36.70M 3.35% 4.10% 2025-12-31
10 Vanguard Capital Management LLC 2,896,004 $32.06M 2.93% 3.14% 2026-06-30
11 FCPM III SERVICES B.V. 2,808,368 $31.09M 2.84% 3.05% 2026-06-30
12 AQR Capital Management, LLC Custodian 2,566,241 $28.41M 2.59% 2.79% 2026-06-30
13 Logos Global Management LP 2,500,000 $27.68M 2.53% 2.71% 2026-06-30
14 Jane Street Group, LLC Custodian 2,322,545 $25.71M 2.35% 2.52% 2026-06-30
15 Erste Asset Management GmbH 2,120,000 $23.74M 2.17% 2.30% 2026-06-30
16 Geode Capital Management, LLC Custodian 2,035,187 $22.53M 2.06% 2.21% 2026-06-30
17 D. E. Shaw & Co., Inc. Custodian 1,789,964 $19.81M 1.81% 1.94% 2026-06-30
18 T. Rowe Price Associates, Inc. 1,620,963 $17.95M 1.64% 1.76% 2026-06-30
19 Opaleye Management Inc. 1,384,993 $15.33M 1.40% 1.50% 2026-06-30
20 TORONTO DOMINION BANK 1,275,000 $14.11M 1.29% 1.38% 2026-06-30
21 UBS Group AG Custodian 1,128,276 $12.49M 1.14% 1.23% 2026-06-30
22 Artisan Partners Limited Partnership 973,496 $10.78M 0.98% 1.06% 2026-06-30
23 FMR LLC Custodian 929,375 $10.29M 0.94% 1.01% 2026-06-30
24 Millennium Management LLC Custodian 821,958 $9.10M 0.83% 0.89% 2026-06-30
25 Citadel Advisors LLC Custodian 784,233 $8.68M 0.79% 0.85% 2026-06-30
16 filers$72.87M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $32.69M 44.86% 2026-06-30
2 Susquehanna International Group, LLP Custodian $12.22M 16.77% 2026-06-30
3 DIADEMA PARTNERS LP $7.71M 10.58% 2026-06-30
4 Citadel Advisors LLC Custodian $7.50M 10.29% 2026-06-30
5 Barclays PLC Custodian $3.50M 4.80% 2026-06-30
6 Simplex Trading, LLC Custodian $3.41M 4.67% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $3.04M 4.17% 2026-06-30
8 Jane Street Group, LLC Custodian $1.50M 2.06% 2026-06-30
9 Persistent Asset Partners Ltd $396.97K 0.54% 2026-06-30
10 Walleye Capital LLC $228.04K 0.31% 2026-06-30
11 PEAK6 LLC $221.40K 0.30% 2026-06-30
12 INGALLS & SNYDER LLC $111.00K 0.15% 2026-06-30
13 Goldman Sachs Group Inc Custodian $110.70K 0.15% 2026-06-30
14 Walleye Trading LLC $109.59K 0.15% 2026-06-30
15 Wolverine Trading, LLC Custodian $75.08K 0.10% 2025-09-30
16 HAP TRADING, LLC $61.60K 0.08% 2025-09-30
18 filers$35.07M notional
# Filer Notional Value % of Total Period
1 DIADEMA PARTNERS LP $5.56M 15.86% 2026-06-30
2 Susquehanna International Group, LLP Custodian $5.33M 15.20% 2026-06-30
3 Citadel Advisors LLC Custodian $5.16M 14.72% 2026-06-30
4 Simplex Trading, LLC Custodian $3.83M 10.92% 2026-06-30
5 Citigroup Inc. Custodian $3.32M 9.47% 2026-06-30
6 Caption Management, LLC $2.45M 6.98% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $2.35M 6.69% 2026-06-30
8 D. E. Shaw & Co., Inc. Custodian $2.21M 6.31% 2026-06-30
9 Millennium Management LLC Custodian $1.87M 5.32% 2026-06-30
10 Jane Street Group, LLC Custodian $1.37M 3.90% 2026-06-30
11 DLD Asset Management, LP $553.00K 1.58% 2026-06-30
12 Verition Fund Management LLC $442.80K 1.26% 2026-06-30
13 TUDOR INVESTMENT CORP ET AL $219.19K 0.62% 2026-06-30
14 Walleye Trading LLC $212.54K 0.61% 2026-06-30
15 Persistent Asset Partners Ltd $115.20K 0.33% 2026-06-30
16 Wolverine Trading, LLC Custodian $60.76K 0.17% 2025-09-30
17 Walleye Capital LLC $11.07K 0.03% 2026-06-30
18 HAP TRADING, LLC $10.00K 0.03% 2025-09-30

REPL Insider Trading (Form 4)

Latest: 2026-08-24
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-24 Philip Astley-Sparke Director Gift (G) −50,000 — EDGAR
2026-08-19 Emily Luisa Hill Chief Financial Officer Sell (S) −9,256 $14.28 -$132.2K EDGAR
2026-08-12 Andrew Schwendenman Chief Accounting Officer Sell (S) −7,632 $12.97 -$99.0K EDGAR
2026-08-12 Emily Luisa Hill Chief Financial Officer Sell (S) −11,448 $12.97 -$148.5K EDGAR
2026-08-12 Konstantinos Xynos Chief Medical Officer Sell (S) −11,447 $12.97 -$148.5K EDGAR
2026-08-12 Sushil Patel Chief Executive Officer Sell (S) −39,341 $12.97 -$510.3K EDGAR
2026-08-11 Julian Baker Director Buy (P) +16,418,040 RSU — EDGAR
2026-06-03 Christopher Sarchi Chief Commercial Officer Sell (S) −12,000 $9.24 -$110.9K EDGAR
2026-05-20 Andrew Schwendenman Chief Accounting Officer Sell (S) −7,894 $5.08 -$40.1K EDGAR
2026-05-20 Sushil Patel Chief Executive Officer Sell (S) −37,324 $5.08 -$189.6K EDGAR
2026-05-20 Emily Luisa Hill Chief Financial Officer Sell (S) −7,812 $5.08 -$39.7K EDGAR
2026-05-20 Christopher Sarchi Chief Commercial Officer Sell (S) −8,626 $5.08 -$43.8K EDGAR
2026-05-20 Konstantinos Xynos Chief Medical Officer Sell (S) −14,023 $5.08 -$71.2K EDGAR
2026-05-20 Philip Astley-Sparke Director Sell (S) −17,657 $5.08 -$89.7K EDGAR
2026-04-07 Christopher Sarchi Chief Commercial Officer Award (A) +50,000 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

REPL Insider Holdings

8 insiders · @ $11.99
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Philip Astley-Sparke Director 1,362,414 $16.34M -$6.90M 21 2026-08-24
2 Sushil Patel Chief Executive Officer 708,151 $8.49M -$1.84M 16 2026-08-12
3 Konstantinos Xynos Chief Medical Officer 224,215 $2.69M -$681.9K 15 2026-08-12
4 Emily Luisa Hill Chief Financial Officer 215,852 $2.59M -$480.9K 11 2026-08-19
5 Christopher Sarchi Chief Commercial Officer 180,962 $2.17M -$412.2K 12 2026-06-03
6 Andrew Schwendenman Chief Accounting Officer 99,425 $1.19M -$180.4K 8 2026-08-12
7 Joseph P Slattery Director 11,867 $142.3K -$139.2K 10 2026-04-07
8 Kapil Dhingra Director 3,169 $38.0K -$1.86M 11 2026-04-07
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

REPL Board & Officers

As of SEC filings through Aug 24, 2026

Directors 16

Officers 4

10% owners 6

Changes in the last 10 years (102)
May 20, 2026Christopher Sarchi reported in an SEC filing no longer being Chief Commercial Officer
May 22, 2025Philip Astley-Sparke no longer listed as Executive Chairman in SEC filings
Mar 5, 2025Michael Goller became a director
Mar 5, 2025Julian Baker became a director
Mar 5, 2025Julian Baker became a 10% owner
Mar 5, 2025Felix Baker became a director
Mar 5, 2025Felix Baker became a 10% owner
Mar 5, 2025Baker Brothers Life Sciences LP became a director
Mar 5, 2025Baker Brothers Life Sciences LP became a 10% owner
Mar 5, 2025Baker Bros. Advisors LP became a director
Mar 5, 2025Baker Bros. Advisors LP became a 10% owner
Mar 5, 2025Baker Bros. Advisors (GP) LLC became a director
Mar 5, 2025Baker Bros. Advisors (GP) LLC became a 10% owner
Mar 5, 2025667, L.p. became a director
Mar 5, 2025667, L.p. became a 10% owner
Sep 4, 2024Madhavan Balachandran became a director
May 20, 2024Philip Astley-Sparke listed as Executive Chairman (previously Chief Executive Officer) in SEC filings
Apr 3, 2024Sushil Patel listed as Chief Executive Officer (previously Chief Strategy Officer) in SEC filings
Apr 3, 2024Sushil Patel first listed as a director in an SEC filing
Sep 18, 2023Emily Luisa Hill became Chief Financial Officer
Not reported recently (13)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

REPL Proposed Insider Sales (Form 144)

Latest: 2026-04-02
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-04-02 Christopher Sarchi Officer 18,500 $142.4K 2026-04-02 J.P. Morgan Securities LLC 10b5-1 EDGAR
2025-12-09 Kapil Dhingra Director 3,164 $32.8K 2025-12-09 J.P. Morgan Securities LLC — EDGAR
2025-12-02 Sushil Patel Chief Strategy Officer 10,000 $111.3K 2025-12-02 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-12-16 Sushil Patel Chief Strategy Officer 15,000 $188.6K 2024-12-16 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-06-07 Konstantinos Xynos Officer 15,881 $119.2K 2024-06-07 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-05-23 Pamela Esposito Officer 79,710 $472.7K 2024-05-23 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-07-10 Pamela Esposito Officer 80,000 $1.69M 2023-07-10 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-06-13 Tanya Lewis Affiliate 22,486 $527.3K 2023-06-13 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-06-13 Sushil Patel Affiliate 23,710 $556.0K 2023-06-13 J.P. Morgan Securities LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
43 ETFs hold REPL
25 shown · $145.24M total exposure · 0.03% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $32.0M — 2026-09-30
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.28% $29.6M $10.4B 2026-10-20
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.03% $23.3M $75.1B 2026-10-20
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $12.0M — 2026-09-30
5 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.06% $8.6M $13.7B 2026-10-20
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.07% $7.7M $11.0B 2026-10-20
7 VTWO Vanguard Russell 2000 ETF Vanguard 0.04% $6.2M — 2026-09-30
8 PTH Invesco Dorsey Wright Healthcare Momentum ETF Nport 1.93% $4.5M — 2026-07-31
9 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $3.1M — 2026-05-31
10 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.23% $2.8M $1.2B 2026-10-20
11 VHT Vanguard Health Care ETF Vanguard 0.01% $2.3M — 2026-09-30
12 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.07% $2.0M — 2026-07-31
13 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.08% $1.5M — 2026-10-20
14 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $1.4M — 2026-10-20
15 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.02% $1.3M $6.6B 2026-10-20
16 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.3M $97.4B 2026-10-20
17 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.19% $1.2M — 2026-10-21
18 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.07% $987,373 — 2026-09-30
19 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $963,323 — 2026-10-20
20 SMIZ Zacks Small/Mid Cap ETF Nport 0.20% $514,587 — 2026-05-31
21 RSSL Global X Russell 2000 ETF Global X 0.03% $453,752 — 2026-10-21
22 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.04% $419,114 $1.0B 2026-10-20
23 BBC Virtus Biotech Clinical Trials Etf Nport 0.84% $392,011 — 2026-07-31
24 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $362,269 — 2026-05-31
25 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $313,525 $10.9B 2026-10-20
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.38
TTM Revenue
—
TTM Net Income
$-313.94M
TTM Op. Cash Flow
$-280.34M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '262026-03-31—$-73.22M$-0.76$-56.16M
Q3 '262025-12-31—$-70.93M$-0.77$-65.95M
Q2 '262025-09-30—$-83.10M$-0.90$-81.21M
Q1 '262025-06-30—$-86.69M$-0.95$-77.02M
Q4 '252025-03-31—$-74.13M$-0.82$-53.73M
Q3 '252024-12-31—$-66.34M$-0.79$-50.71M
Q2 '252024-09-30—$-53.05M$-0.68$-38.64M
Q1 '252024-06-30—$-53.77M$-0.78$-49.17M
Q4 '242024-03-31—$-55.08M$-0.82$-46.17M
Q3 '242023-12-31—$-51.12M$-0.77$-47.12M
Q2 '242023-09-30—$-60.04M$-0.90$-43.59M
Q1 '242023-06-30—$-49.55M$-0.75$-48.59M
Q4 2026 • period ending 2026-03-31 • filed 2026-06-29
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
6.65
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-188.9%
ROA
-94.4%
Div Yield
0.00%
FCF Yield
-25.39%
Debt/Equity
0.63
Current Ratio
—
Market Cap
$1.10B
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
23.13M
SI % of Float
29.54%
Days to Cover
10.83
Short Vol Ratio
46.4%
Free Float
78.30M
Float %
83.5%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-22